Home

The study is designed to answer key questions arising from the October 2020 Circulatory Systems Devices Panel Meeting regarding the Neovasc Reducer. The approval of the supplement is consistent with Neovasc’s internal target, and the company remains on track to enrol the first patient in the trial late this year.

COSIRA-II is a randomised, sham-controlled trial investigating the safety and effectiveness of the Reducer for patients suffering from refractory angina. The primary endpoint of the trial is change in exercise tolerance testing time via a modified Bruce protocol between baseline and six-month follow-up.

The study is planned to enrol approximately 380 patients at up to 50 sites in the USA and will also include limited sites outside of the USA. The trial will include patients with Canadian Cardiovascular Society Class III-IV refractory angina on maximally tolerated medical therapy without further options for revascularisation via coronary intervention or bypass grafting. The principal investigators of the trial are Gregg Stone (Mount Sinai Health System, New York, USA) and Tim Henry (Christ Hospital, Cincinnati, USA).

FDA approval of the IDE Supplement is another important milestone for Neovasc, commented Lisa Becker, vice president of regulatory affairs, Global Angina Therapies, at Neovasc. “We are grateful for the collaborative work with FDA and we are pleased that our study initiation remains on track”, she continued. “Refractory angina is a debilitating condition, and we are excited to offer patients in the USA and Canada a clinical trial with a treatment option that may alleviate their suffering.”

The Reducer is CE-marked in the European Union and under investigation in the USA for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularisation or cardiac drug therapies

While the Reducer is not approved for commercial use in the USA, the FDA granted Breakthrough Device designation to the Reducer in October 2018.

Source CardiovascularNews

Duc Tin Clinic

$Chia sẽ qua facebook bài: Neovasc to begin COSIRA-II trial of Reducer for refractory angina$ $Chia sẽ qua google bài: Neovasc to begin COSIRA-II trial of Reducer for refractory angina$ $Chia sẽ qua twitter bài: Neovasc to begin COSIRA-II trial of Reducer for refractory angina$ $Chia sẽ qua MySpace bài: Neovasc to begin COSIRA-II trial of Reducer for refractory angina$ $Chia sẽ qua LinkedIn bài: Neovasc to begin COSIRA-II trial of Reducer for refractory angina$ $Chia sẽ qua stumbleupon bài: Neovasc to begin COSIRA-II trial of Reducer for refractory angina$ $Chia sẽ qua icio bài: Neovasc to begin COSIRA-II trial of Reducer for refractory angina$ $Chia sẽ qua digg bài: Neovasc to begin COSIRA-II trial of Reducer for refractory angina$ $Chia sẽ qua yahoo bài: Neovasc to begin COSIRA-II trial of Reducer for refractory angina$ $Chia sẽ qua yahoo bài: Neovasc to begin COSIRA-II trial of Reducer for refractory angina$ $Chia sẽ qua yahoo bài: Neovasc to begin COSIRA-II trial of Reducer for refractory angina$ $Chia sẽ qua yahoo bài: Neovasc to begin COSIRA-II trial of Reducer for refractory angina$

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.